An article in Martha Vineyard Times announced that phase 3 trials for the Valneva-Pfizer Lyme disease vaccine candidate, VLA15, will take place on the Vineyard. This trial phase will investigate the extent to which the vaccine provides protection.
Search Results for: vaccine
Valneva and Pfizer have announced that the two companies have entered into an Equity Subscription Agreement and have updated their Collaboration and License Agreement terms for the Lyme disease vaccine candidate, VLA15. As previously announced, Pfizer plans to begin Phase 3 studies of VLA15 in Q3 2022.
Positive Phase 2 clinical trial results for the Lyme disease vaccine candidate (VLA15) in the pediatric population have just been announced by Pfizer and Valneva. VLA15 is currently the only Lyme disease vaccine candidate in clinical development, and is the first clinical study to enroll children aged 5 to 17 years old. This phase 2 […]
National Geographic has published an article that discusses a renewed effort to develop a highly controversial technology, ”contagious/self-spreading vaccines.” This vaccine technology is being reexamined and studied to stop the spread of many zoonotic diseases. Several teams of researchers from around the world are reviving the controversial research that began in the 1980’s. The goal […]
The FDA has just announced that they plan to postpone their scheduled advisory committee meeting on Pfizer’s COVID-19 vaccine for children ages 6 months to 4 years. They do not expect to reconvene for a few more months pending additional data required to move forward. A two-dose vaccine series failed to meet “immunobridging” criteria […]
In a February 4, 2022 news release Valneva/Pfizer reported positive Phase 2 data findings for their Lyme disease vaccine candidate, VLA15. According to the news release, findings of the Phase 2 trial show there is value in adding a third dose of vaccine. In the Phase 2 clinical trial, researchers found a stronger immune response […]
Giving Tuesday: Help LDA Help You/Persistence of Lyme Bacteria/Lyme Bacteria in Bats/Lyme: mRNA Vaccine/Shrews Harbor Powassan Virus/Another Lyme Bacteria in Ticks/LymeAid 4 Kids
Two Literati with Lyme authors had this to say about supporting the Lyme Disease Association’s Giving Tuesday campaign: Amy Tan- Internationally acclaimed author who helped initiate LDA’s LymeAid 4 Kids: “It’s Giving Tuesday! Many thanks to those who give generously to enable kids to get properly diagnosed and treated. You are making a profound difference in the lives of kids and their families.”
Sajid, et al., published in the journal Science Translational Medicine about the development of a promising mRNA vaccine, 19ISP, which has been found to induce tick resistance and prevent transmission of the Lyme disease-causing agent, Borrelia burgdorferi (Bb).
Ticks & Biowarfare Investigation Passes House/Last Chance to Register for LDA Conf. Before Price Increase/COVID Impacts on Lyme Reporting/Monoclonal Antibody COVID Treatment/LDA Doctor Referral Now Open/Valneva Lyme Vaccine
The Lyme Disease Association announces that the House voted this week to pass a number of amendments to the NDAA, National Defense Authorization Act, including a Congressman Chris Smith amendment.
Findings of a recent study, Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence, show that Moderna’s COVID-19 vaccine appears to have a higher effectiveness rate compared with the Pfizer vaccine. This observational study was conducted from a Minnesota patient cohort in July 2021. Both vaccines appeared to […]